NEWS

Global Coalition for Adaptive Research Announces That Regorafenib Has Completed Follow-up in the GBM AGILE Trial for Patients With Glioblastoma
SEPTEMBER 21, 2022  |  BUSINESSWIRE
Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven’s Troriluzole and Vigeo’s VT1021 in GBM AGILE Trial
JULY 6, 2022  |  BUSINESSWIRE
GBM AGILE Opens to Paxalisib in Europe
MAY 31, 2022  |  KAZIA THERAPEUTICS
Kintara Announces First European Site Activation in Switzerland in GCAR Phase 2/3 Clinical Trial for Glioblastoma
MAY 27, 2022  |  PRNEWSWIRE
Global Coalition for Adaptive Research Announces the Discontinued Evaluation of Eritoran in REMAP-COVID
MAY 19, 2022  |  BUSINESSWIRE
Cure Brain Cancer Foundation invests in GBM AGILE, connecting Australians to an innovative clinical trial program to treat glioblastoma
FEBRUARY 22, 2022  |  CURE BRAIN CANCER FOUNDATION
Vigeo Therapeutics Advances VT1021 Into Phase 2-3 Registrational Study for Glioblastoma
JANUARY 20, 2022  |  VIGEO THERAPEUTICS
Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non–Critically Ill Hospitalized Patients With COVID-19
JANUARY 18, 2022  |  JAMA
Global Coalition for Adaptive Research Announces Key Updates on GBM AGILE Phase 2-3 Adaptive Platform Trial for Patients With Glioblastoma
JANUARY 18, 2022  |  BUSINESSWIRE
Kintara Announces First International Site Activation in GCAR Phase 2/3 Clinical Trial for Glioblastoma
NOVEMBER 30, 2021  |  PRNEWSWIRE
GBM AGILE Opens to Paxalisib in Canada
NOVEMBER 29, 2021  |  KAZIA THERAPEUTICS
Ovarian CanceRx: New Innovative Clinical Research Effort Seeks to Accelerate the Development of New Treatments for Deadliest Gynecological Cancer
SEPTEMBER 23, 2021  |  BUSINESSWIRE
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19
AUGUST 4, 2021  |  NEJM
Global Coalition for Adaptive Research Announces the Discontinued Evaluation of Apremilast in REMAP-COVID
July 12, 2021  |  BUSINESSWIRE
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
FEBRUARY 25, 2021  |  NEJM
Henry Ford Cancer Institute is First in the World to Activate Two New Treatments in GBM AGILE Trial for Glioblastoma
FEBRUARY 3, 2021  |  NEWSWISE
Implementation of the Randomized Embedded Multifactorial Adaptive Platform for COVID-19 (REMAP-COVID) trial in a US health system—lessons learned and recommendations
JANUARY 28, 2021  |  BIOMED CENTRAL
Full-dose blood thinners decreased need for life support and improved outcome in hospitalized COVID-19 patients
JANUARY 22, 2021  |  NATIONAL INSTITUTES OF HEALTH
Global Coalition for Adaptive Research, Kazia, and Kintara Announce Commencement of Kazia’s Paxalisib and Kintara’s VAL-083 in GBM AGILE Trial
JANUARY 6, 2021  |  BUSINESSWIRE
Global Coalition for Adaptive Research, Amgen, and Eisai Announce First Patient Enrolled in International COVID-19 Trial
OCTOBER 26, 2020  |  BUSINESSWIRE
Kintara and the Global Coalition for Adaptive Research Execute Agreement for VAL-083’s Participation in the GBM AGILE Registrational Study
OCTOBER 21, 2020  |  PRNEWSWIRE
Kazia Executes Agreement to Commence GBM AGILE Pivotal Study
OCTOBER 16, 2020  |  Kazia Therapeutics
Steroids Can Be Lifesaving for Covid-19 Patients, Scientists Report
SEPTEMBER 2, 2020  |  NEW YORK TIMES
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19. The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial
SEPTEMBER 2, 2020  |  JAMA
Corticosteroids Improve Survival in Critically Ill COVID-19 Patients
SEPTEMBER 2, 2020  |  EUREKALERT
REMAP-CAP to Partner With Eisai on Innovative Trial to Combat COVID
JUNE 30, 2020  |  BUSINESSWIRE
DelMar Pharmaceuticals Receives $500,000 Loan from the National Brain Tumor Society and National Foundation for Cancer Research to Support VAL-083’s Participation in a Pivotal Study for Glioblastoma Sponsored by the Global Coalition for Adaptive Research
JUNE 24, 2020  |  PRNEWSWIRE
Global Coalition for Adaptive Research (GCAR) Selects DelMar Pharmaceuticals’ VAL-083 to Participate in the GBM AGILE Pivotal Study, an Adaptive Clinical Trial Platform in Glioblastoma Multiforme
JUNE 4, 2020  |  PRNEWSWIRE
Chasing a Cure for GBM: Investigators Test Multiple Regimens in Novel Trial
MAY 14, 2020  |  ONCLIVE
International trial uses AI to rapidly identify optimal Covid-19 treatments
APRIL 9, 2020  |  STAT
Kazia Initiates Preparatory Activities to Bring GDC-0084 into GBM AGILE, an International Phase II / III Study in Glioblastoma
December 11, 2019  |  PRNEWSWIRE
Henry Ford Cancer Institute Enrolls First Patient in World’s Largest Brain Cancer Clinical Trial
AUGUST 14, 2019  |  BIO SPACE
Global Coalition for Adaptive Research’s Innovative Clinical Trial Platform Opens to Evaluate New Therapies for Brain Cancer
JUNE 19, 2019  |  BUSINESS WIRE
Global Coalition for Adaptive Research (GCAR) Appoints Jeffrey Tarrant to Board of Directors
JUNE 13, 2019  |  BUSINESS WIRE
FDA’s Woodcock Defends Accelerated Approvals and Talks of Culture Shift in Clinical Trials
JUNE 5, 2019  |  BIOPHARMA DIVE
New Funding & Partnership Bolsters Support for First Global Adaptive Clinical Trial Platform for Brain Cancer Patients
MAY 1, 2019  |  NATIONAL BRAIN TUMOR SOCIETY
Global Coalition for Adaptive Research (GCAR) Names Meredith Buxton Chief Operating Officer
JANUARY 31, 2019  |  GLOBAL COALITION FOR ADAPTIVE RESEARCH
National Brain Tumor Society Invests in GBM AGILE, the World’s First Global Adaptive Trial for Glioblastoma
JANUARY 16, 2019  |  NATIONAL BRAIN TUMOR SOCIETY
Bayer’s Regorafenib is the First Drug to Enter GBM AGILE
NOVEMBER 14, 2018  |  BUSINESSWIRE
Global Coalition for Adaptive Research (GCAR) Names Gary Gordon Interim Chief Executive Officer
NOVEMBER 8, 2018  |  PRWEB
4 Ways Cancer is Changing How We Test Medicines
OCTOBER 18, 2018  |  POLITICO
Dr. W.K. Alfred Yung Addresses Members of U.S. Congress at Glioblastoma Event Hosted by NBTS, Senator Lindsey Graham
May 16, 2018  |  National Brain Tumor Society
Global Coalition for Adaptive Research Launches to Speed the Discovery & Development of Cures for Patients with Rare & Deadly Diseases
April 16, 2018  |  BusinessWire
Could a New Business Model Make Clinical Drug Trials More Accessible to Patients?
March 8, 2018  |  Harvard Business School
W.K. Alfred Yung, M.D. – Smart Bomb Virus Shows Promise as Brain Tumor Immunotherapy
FEBRUARY 12, 2018  |  UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
Dr. Brian M. Alexander – Kraft Precision Medicine Accelerator has met with the US Food and Drug Administration to Discuss Standardizing Platform Methodologies
January 15, 2018  |  Harvard Business School
Joe Biden Recognizes Dr. W.K. Alfred Yung on The View
December 13, 2017  |  ABC’s ‘The View’
Advancing Oncology Platform Trials
December 12-13, 2017  |  Dr. Brian M. Alexander, MIT Next Wave Forum 2017
Dr. Webster K. Cavenee Elected to the Chinese Academy of Engineering
November 28, 2017  |  Chinese Academy of Engineering
Dr. Brian M. Alexander – Adaptive Platform Trials: The Clinical Trial of the Future?
September 26, 2017  |  Ariel D. Stern and Sarah Mehta, Harvard Business Review
Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE
September 20, 2017  |  Dr. Brian M. Alexander, Dr. Sujuan Ba, Dr. Webster Cavenee, Dr. Timothy F. Cloughesy, Dr. W.K. Alfred Yung - American Association for Cancer Research
Dr. Sujuan Ba Wins International Cooperation Award from the Chinese Medical Doctor Association
March 27, 2017  |  NATIONAL FOUNDATION FOR CANCER RESEARCH
Dr. W.K. Alfred Yung Presents Joe Biden, Dr. Jill Biden With Commemorative Plaque at MD Anderson’s Diamond Gala
November 17, 2016  |  University of Texas MD Anderson Cancer Center
Dr. Webster K. Cavenee Receives 2016 Chinese Government Friendship Award
September 28, 2016  |  Chinese Vice Premier Ma Kai
The Billion Dollar Statistical Concept
August 10, 2016  |  Dr. Scott Berry
I-SPY 2 and Other Platform Trials
May 1, 2015  |  Dr. Don Berry
The Adaptive Platform Trial – The Statistical Efficiencies
March 6, 2015  |  Dr. Scott Berry